Product Details
| Alternative Name: | TNFSF 15, VEGI |
| |
| MW: | ~20kDa (SDS-PAGE). |
| |
| Source: | Produced in E. coli. The extracellular domain of human TL1A (aa 93-251) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag. |
| |
| UniProt ID: | O95150 |
| |
| Concentration: | 0.1mg/ml after reconstitution. |
| |
| Formulation: | Lyophilized. Contains PBS. |
| |
| Purity: | ≥85% (SDS-PAGE) |
| |
| Endotoxin Content: | <0.1EU/µg purified protein (LAL test; Associates of CAPE COD Inc.). |
| |
| Specificity: | Binds human DR3 and DcR3. |
| |
| Applications: | ELISA, Flow Cytometry
|
| |
| Application Notes: | Flow Cytometry: use together with Enhancer for Ligands (Prod. No. ALX-804-034) to detect human DR3 and DcR3. |
| |
| Reconstitution: | Reconstitute with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein. |
| |
| Shipping: | Shipped on Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
| |
| Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C. |
| |
| Scientific Background: | TL1A (TNFSF15), a ligand belonging to the tumor necrosis factor (TNF) family, is expressed predominantly by endothelial cells and monocytes. TL1a is upregulated by the proinflammatory cytokines TNF and IL-1 and also by immune complexes (IC). TL1 functions in T cell costimulation and Th1 polarization. On activated T cells, TL1A functions specifically via its surface-bound receptor DR3, (a member of the death-domain containing TNF receptor family) to promote cell survival and secretion of proinflammatory cytokines (1). The secreted decoy receptor 3 (DcR3), a soluble protein of the tumor necrosis factor receptor (TNFR) superfamily blocks the action of TL1A. TL1A can be released to circulate as a homotrimeric soluble form. Activation of DR3 by TL1A induced the formation of a signaling complex containing TRADD, TRAF2, and RIP and activated the NF-κB and the ERK, JNK, and p38 mitogen-activated protein kinase pathways. The TL1A/DR3 pathway plays an important role in Th1-mediated intestinal diseases, such as Crohn’s disease. |
| |
| Technical Info/Product Notes: | FLAG is a registered trademark of Sigma-Aldrich Co. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
General Literature References
Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis: M.A. Cassatella, et al.; J. Immunol.
178, 7325 (2007),
Abstract;
Identification of naturally secreted soluble form of TL1A, a TNF-like cytokine: S. Kim & L. Zhang; J. Immunol. Methods
298, 1 (2005),
Abstract;
Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3: M.J. Hsu, et al.; Exp. Cell Res.
292, 241 (2004),
Abstract;
Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease: G. Bamias, et al.; J. Immunol.
171, 4868 (2003),
Abstract;
TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells: L. Wen, et al.; J. Biol. Chem.
278, 39251 (2003),
Abstract;
Full Text
TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator: T.S. Migone, et al.; Immunity
16, 479 (2002),
Abstract;
Related Products
